Exelixis Inc Restructuring and Related Cost, Number of Positions Eliminated
Exelixis Inc (EXEL) reported Restructuring and Related Cost, Number of Positions Eliminated of 386 employee for the 12-month period ending 2010-12-31, per its 10-Q filed 2012-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2012-11-07
employee
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|
| 2010-12-31 | 386.00 employee 10-Q · filed 2012-11-07 |
employees
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|
| 2010-12-31 | 386.00 employees 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |